Nephrogenic fibrosing dermopathy is the original name for a rare and serious disease now known as nephrogenic systemic fibrosis.

The first cases of nephrogenic systemic fibroses were identified in 1997, but the disorder was first acknowledged as an independent disease in 2000. While not fully understood, patients with the disease develop large areas of hardened skin with fibrotic nodules and plaques, resulting in a limitation in their range of motion. As the disease was studied, it was found to also affect internal organs. Prior to this discovery, the disorder was known as nephrogenic fibrosing dermopathy.

In recent years, NSF has been linked to gadolinium exposure. Most commonly, patients have been administered a gadolinium-based MRI contrast agent. Patients with severe renal failiure, who are given such a contrast agent, have the highest risk of developing NSF.

If you have been diagnosed with NFD or NSF after using a gadolinium-based contrast agent, you may be entitled to financial compensation. For more information on NSF lawsuits, please contact the NSF attorneys of Williams Kherkher by calling 800-761-3187.